Get our introductory offer at only
*$0.99/month for first 3 months
$29.90/month for the next 9 months
NOVARTIS AG proposed buying back US$5 billion of shares and said it's considering separating its embattled eye-care division after projecting that sales this year at Europe's second-biggest drugmaker will likely be largely unchanged from 2016.
Earnings, excluding some